Ausdal Financial Partners’s ARK Genomic Revolution ETF ARKG Stock Holding History

Ausdal Financial Partners’s Portfolio ARKG Stock Details ARKG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-6,683	Closed	-$409K	–	490
2021 Q4	$409K	Sell	6,683 -2,294	-26%	-$159K	0.05%	322
2021 Q3	$671K	Sell	8,977 -19,658	-69%	-$1.65M	0.1%	229
2021 Q2	$2.65M	Buy	28,635 +10,669	+59%	+$907K	0.4%	76
2021 Q1	$1.59M	Sell	17,966 -13,274	-42%	-$1.32M	0.27%	111
2020 Q4	$2.91M	Buy	31,240 +27,321	+697%	+$2.18M	0.57%	49
2020 Q3	$250K	Buy	+3,919	New	+$230K	0.06%	292

Other funds holding ARKG

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

MCMC

Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return

State of Wisconsin Investment Board Madison, Wisconsin $43.7B AUM 27.76% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Ausdal Financial Partners's ARKG Position: Q1 2022 in Review

Ausdal Financial Partners sold out of ARK Genomic Revolution ETF (ARKG) in Q1 2022, closing a stake of 6,683 shares — an estimated $409K sold.

Ausdal Financial Partners first reported a position in ARKG in Q3 2020 and held it in 6 quarters. The position peaked at $2.91M in Q4 2020. 387 funds tracked by Wall St. Rank hold ARKG as of Q1 2022.

Ausdal Financial Partners reported no remaining ARK Genomic Revolution ETF position as of Q1 2022 after selling out during the quarter.
Ausdal Financial Partners sold 6,683 ARK Genomic Revolution ETF shares in Q1 2022, an estimated $409K.
Ausdal Financial Partners first reported a position in ARK Genomic Revolution ETF in Q3 2020 and held it in 6 quarters.
Ausdal Financial Partners's ARK Genomic Revolution ETF position peaked at $2.91M in Q4 2020.
387 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q1 2022.

Based on Ausdal Financial Partners's 13F filing for Q1 2022, filed 4 May 2022.